Global InformationOnyema Ogbuagu information
Onyema Eberechukwu Ogbuagu (born June 20, 1978) is an American-born infectious diseases physician, educator, researcher, and clinical trial investigator, who was raised and educated in Nigeria. He is an associate professor at Yale School of Medicine in New Haven, CT and is the director of the Yale AIDS Program clinical trials unit.[1] His research contributions have focused on HIV/AIDS prevention and COVID-19 vaccination and treatment clinical trials.[2] He switched his focus at the beginning of the 2019 COVID pandemic and participated as a principal investigator (PI) on the Pfizer-BioNtech COVID-19 vaccine trials [3][4] and the Remdesivir SIMPLE trial[5] in 2020 and 2021. In pursuit of his global health component of his career, Ogbuagu also supports postgraduate physician medical education programs in low and middle income countries in sub-Saharan Africa in Rwanda (2013–2018) and Liberia (2017 to date) as well as HIV treatment programs in Liberia (2018 to date).
In his role as public health educator, he has worked to increase public understanding of mRNA vaccines.[6][7][8][9][10][11] Ogbuagu has also worked to decrease vaccine hesitancy.[12][13] He has been a co-author on 43 scholarly articles, according to the National Library of Medicine.[14] According to Google Scholar, one article he co-authored on Remdesivir and its use for Covid that appeared in JAMA was cited 504 times.[15] Ogbuagu was selected as the commencement speaker for Yale School of Medicine's class of 2021.[16]
- ^ "Onyema Ogbuagu, MBBCh, FACP, FIDSA". medicine.yale.edu. Retrieved 2021-06-17.
- ^ Sopeyin, Anuoluwapo; Hornsey, Emilio; Okwor, Tochi; Alimi, Yewande; Raji, Tajudeen; Mohammed, Abdulaziz; Moges, Hiwot; Onwuekwe, Ezinne V C.; Minja, Frank J.; Gon, Giorgia; Ogbuagu, Onyema; Ogunsola, Folasade; Paintsil, Elijah (2020). "Transmission risk of respiratory viruses in natural and mechanical ventilation environments: Implications for SARS-CoV-2 transmission in Africa". BMJ Global Health. 5 (8): e003522. doi:10.1136/bmjgh-2020-003522. PMC 7462043. PMID 32863269.
- ^ Frenck, Robert W.; Klein, Nicola P.; Kitchin, Nicholas; Gurtman, Alejandra; Absalon, Judith; Lockhart, Stephen; Perez, John L.; Walter, Emmanuel B.; Senders, Shelly; Bailey, Ruth; Swanson, Kena A. (2021-07-15). "Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents". The New England Journal of Medicine. 385 (3): 239–250. doi:10.1056/NEJMoa2107456. ISSN 1533-4406. PMC 8174030. PMID 34043894.
- ^ Polack, Fernando P.; Thomas, Stephen J.; Kitchin, Nicholas; Absalon, Judith; Gurtman, Alejandra; Lockhart, Stephen; Perez, John L.; Pérez Marc, Gonzalo; Moreira, Edson D.; Zerbini, Cristiano; Bailey, Ruth (2020-12-31). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". The New England Journal of Medicine. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. ISSN 1533-4406. PMC 7745181. PMID 33301246.
- ^ Spinner, Christoph D.; Gottlieb, Robert L.; Criner, Gerard J.; Arribas López, José Ramón; Cattelan, Anna Maria; Soriano Viladomiu, Alex; Ogbuagu, Onyema; Malhotra, Prashant; Mullane, Kathleen M.; Castagna, Antonella; Chai, Louis Yi Ann (2020-09-15). "Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial". JAMA. 324 (11): 1048–1057. doi:10.1001/jama.2020.16349. ISSN 0098-7484. PMC 7442954. PMID 32821939.
- ^ Julia Hollingsworth, Adam Renton, Emma Reynolds, Nada Bashir, Melissa Macaya and Meg Wagner (2020-12-10). "Pfizer principal investigator "very optimistic" about positive news after FDA meeting". CNN. Retrieved 2021-06-17.
{{cite web}}: CS1 maint: multiple names: authors list (link) - ^ "Video: What you need to know about COVID-19 vaccine distribution". ABC News. Retrieved 2021-06-17.
- ^ "Low public trust could hurt vaccine distribution in minority communities". MSNBC.com. Retrieved 2021-06-17.
- ^ New Pfizer trial shows vaccine 100% effective in teens 12-15, retrieved 2021-06-17
- ^ Johnson, Carolyn Y. (27 August 2020). "Large U.S. covid-19 vaccine trials are halfway enrolled, but lag on participant diversity". Washington Post. Retrieved 2021-06-17.
- ^ "Connecticut's Shot in the Arm: State leaders, health officials discuss COVID-19 vaccine". WTNH.com. 2020-12-02. Retrieved 2021-08-30.
- ^ "T.D. Jakes Hosts Conversation with COVID-19 Vaccine Scientists". www.prnewswire.com (Press release). Retrieved 2021-06-17.
- ^ "COVID Vaccines and the Return to Life: Part 1". The Aspen Institute. Retrieved 2021-07-02.
- ^ "Onyema Ogbuagu - Search Results - PubMed". PubMed. Retrieved 2021-06-23.
- ^ Spinner, Christoph D.; Gottlieb, Robert L.; Criner, Gerard J.; Arribas López, José Ramón; Cattelan, Anna Maria; Soriano Viladomiu, Alex; Ogbuagu, Onyema; Malhotra, Prashant; Mullane, Kathleen M.; Castagna, Antonella; Chai, Louis Yi Ann (2020-09-15). "Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial". JAMA. 324 (11): 1048–1057. doi:10.1001/jama.2020.16349. ISSN 0098-7484. PMC 7442954. PMID 32821939.
- ^ "MD Class of 2021 Selects Associate Professor Onyema Ogbuagu as Commencement Speaker". medicine.yale.edu. Retrieved 2021-06-17.